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Abstract
Background: Sedation is an important consideration in the care of the neurocritically ill patient. It provides anxiety
and relief, facilitates procedures and nursing tasks, and minimizes intolerance of mechanical ventilation. Alpha-2
agonists such as dexmedetomidine and clonidine have been shown to be an effective alternative in the general
critical care population by reducing duration of mechanical ventilation and length of stay in the intensive care unit
(ICU), as compared to traditional sedative agents such as propofol or benzodiazepines. However, there is a paucity
of literature detailing their utility and safety in neurocritical care, a population that presents unique considerations
for management of global and cerebral hemodynamics, agitation, and facilitation of neurological assessments. The
objective of this review is to assess the efficacy and safety of alpha-2 agonists for non-procedural sedation in
mechanically ventilated brain-injured patients.
Methods: We will search the Embase and MEDLINE databases for all randomized controlled trials, prospective and
retrospective cohort studies examining neurocritically ill adult patients aged 18 years and older who are on
mechanical ventilation and receiving alpha-2 agonists for non-procedural sedation. Primary outcomes of interest
include effect on mean arterial pressure (MAP), intracranial pressure (ICP), and cerebral perfusion pressure (CPP).
Secondary outcomes include adverse events, duration of mechanical ventilation, 30-day mortality, ICU length of
stay, incidence of delirium, and quality of sedation. Continuous outcomes will be presented as means and mean
differences and discrete counting events will be presented as event rates. Pre-defined criteria for heterogeneity are
provided for determination of pooling eligibility. Where appropriate, we will pool estimates for individual outcomes.
Planned subgroup analyses include specific alpha-2 agonist agent, study design, clinical diagnosis, dosing regimen,
and use of adjunctive agents. Quality of evidence for the recommendation will be assessed using the Grading of
Recommendations, Assessment, Development and Evaluation (GRADE) approach where appropriate.
Discussion: This systematic review will summarize the evidence on the efficacy and safety for the use of alpha-2
agonists as sedative agents in the neurocritical care population.
Systematic review registration: PROSPERO CRD42016037045
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Background
Description of the condition
Sedation is an important component in the care of crit-
ically ill patients requiring mechanical ventilation. Goals
of sedation in medical and surgical intensive care units
(ICU) commonly include reductions in pain, anxiety,
catecholamine activity and oxygen demand [1], facilita-
tion of procedures or nursing care, and minimization of
ventilator dyssynchrony [2].
Sedation for the critically ill patient presents an array
of challenges and adverse consequences. It is associated
with the development of delirium, which in turn may
lead to prolonged hospitalization and worse patient out-
comes [3]. The challenging and unpredictable pharma-
cokinetics and pharmacodynamics of the critically ill
patient may result in drug accumulation, prolonged drug
effect, and sleep disturbances. Oversedation of patients
leads to prolonged weaning from ventilation, unreliable
neurologic and delirium screening assessments, and in-
creased risk of post-traumatic stress disorder after dis-
charge [4]. In addition, many classes of sedative agents
may cause adverse hemodynamic events including
hypotension and arrhythmias [5].
ICU populations are very heterogeneous groups of pa-
tients. Head injury is a common cause for ICU admis-
sion and is often accompanied with severe rates of
mortality and morbidity [6]. In the specific ICU patient
sub-population with significant intra-cranial pathology,
the intensivist faces a rather unique set of considerations
when selecting sedative agents. These include the need
for optimization of intracranial pressure (ICP), cerebral
perfusion pressure (CPP), and cerebral oxygen consump-
tion, and the management of neurogenic hyperventila-
tion and treatment of aggressive agitation or delirium
[7]. The intensivist must manage a number of factors to
which the neurocritical patient is uniquely sensitive,
such as blood pressure, oxygenation, carbon dioxide,
temperature, and glucose levels in balance with the need
for frequent and accurate neurologic assessments.
Failure to appropriately address these considerations can
potentially result in catastrophic outcomes.
Despite a wide selection of available drug classes, there
is little consensus regarding an optimal agent or regi-
men. Systematic reviews of randomized controlled trials
in medical and surgical ICUs evaluating commonly used
agents such as propofol, midazolam, or other sedatives
demonstrated conflicting results regarding weaning
duration, length of stay, quality of sedation, and rates of
adverse events [3, 8–12].
Description of the intervention
Alpha-2 agonists, such as dexmedetomidine and cloni-
dine, have gained recent popularity as sedative agents in
neurocritical patients. They provide sedative, anxiolytic,
and some analgesic effects without causing respiratory
depression [2]. The properties of alpha-2 agonists allow
for their effective use in procedural sedation and reduce
the need for adjunctive anxiolytics or opioids [13]. In
addition, there is a pre-clinical evidence to suggest a
direct neuroprotective effect in traumatic brain injury
models [14]. Within the intensive care setting, alpha-2
agonists have been demonstrated to reduce the duration
of mechanical ventilation and ICU length of stay as
compared to traditional sedatives such as propofol or
benzodiazepines [2]. These improved outcomes could be
due to better arousal, easier communication, retained
spontaneous respiration, and reduction in delirium.
Clonidine has historically been used quite commonly in
adult ICUs despite a paucity of literature to evaluate its
effectiveness [15]. Dexmedetomidine, an IV formulation
introduced more recently, is known to be considerably
more expensive than traditional sedatives, but offers
considerable overall savings due to lower occurrence of
delirium and shorter time to extubation [16, 17]. There
is no previous literature comparing clonidine and
dexmedetomidine directly.
How the intervention might work?
Alpha-2 agonists bind to transmembrane G protein-
binding adrenergic receptors in the periphery (alpha-2a
subtype) as well as in the brain and spinal cord (alpha-2b
and alpha-2c subtypes) [13]. The activation of these recep-
tors leads to suppression of neuronal activity and inhib-
ition of norepinephrine release, particularly in the locus
coeruleus, the principal site for norepinephrine synthesis
in the brain [18]. These agents therefore have profound
effects on the modulation of anxiety, arousal, and sleep. In
addition, alpha-2 agonists may present hemodynamic
effects, resulting most commonly in hypotension and mild
bradycardia via direct sympatholytic effects [5]. Clonidine,
more so than dexmedetomidine, has been implicated as a
cause of rebound hypertension following its discontinu-
ation. These potential hemodynamic effects directly affect
ICP, CPP, and the resultant cerebral blood flow.
Why it is important to do this review?
The use of alpha-2 agonists for non-procedural sedation
in critical care is a relatively novel concept and patterns
of use vary worldwide. Certain jurisdictions (e.g., Europe)
have had access to the IV formulation of alpha-2 agonists
like clonidine for some time whereas this has only been
possible in Canada more recently with the development of
dexmedetomidine. A recent systematic review by the
Cochrane Collaboration demonstrated that compared
with traditional sedatives, dexmedetomidine shortened
the duration of mechanical ventilation and ICU length of
stay in the general critical care population [2]. There was
no evidence for a difference in delirium or mortality.
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However, there was no specific analysis for the acute brain
injury population or safety evaluation of key neurologic
care indicators such as ICP or CPP. Another systematic
review by Roberts et al. studied critically ill adults with
severe traumatic brain injury but evaluated only trad-
itional sedatives such as propofol, benzodiazepines, and
opioid analgesics [12]. The management of the critically ill
brain-injured patient requires frequent and reliable neuro-
logical assessment, as well as special consideration given
to global and cerebral hemodynamics. Given these unique
challenges, a comprehensive analysis is needed to assess
the safety and efficacy of alpha-2 agonists for long-term
sedation in this patient population.
Objective
The objective of this review is to assess the efficacy and
safety of alpha-2 agonists for non-procedural sedation in
critically ill, mechanically ventilated brain-injured adult
patients.
Methods/design
This systematic review protocol was designed using the
Preferred Reporting Items for Systematic Review and
Meta-Analyses Protocol (PRISMA-P) checklist (see Add-
itional file 1) [19, 20]. This protocol has been registered
with the PROSPERO International Prospective Register of
Systematic Reviews (PROSPERO # CRD42016037045).
Any subsequent amendments made to the protocol during
the review process will be clearly outlined and discussed
in the review manuscript.
Eligibility criteria
Studies will be selected according to the criteria out-
lined below. The criteria have been outlined accord-
ing to the PICOS (Population, Intervention,
Comparator, Outcomes, Study Design) framework.
Population
We will include all studies examining neurocritically ill
adult patients (age ≥18 years) who are on invasive mech-
anical ventilation and require non-procedural sedation.
Neurocritically ill patients are defined as those admitted
to an ICU with a primary neurological diagnosis, such as
a stroke, hemorrhage, traumatic brain injury, or post-
neurosurgical care. Studies with a mixed ICU population
will be included if at least 50 % of the population is com-
posed of neurocritically ill patients, or if a separate
neurocritical care subgroup is clearly presented within
the study. In instances of lack of clarity, clarification
with the corresponding author will be attempted. Studies
composed of mixed invasive and non-invasive ventila-
tion patients will be included. Studies evaluating patients
without neurological diagnoses or mechanical ventilation
will be excluded.
Intervention
The intervention of interest is the use of an alpha-2
agonist as an agent for non-procedural sedation. The
alpha-2 agonist can be administered as a stand-alone or
adjunctive agent. There is no limit on dose, frequency,
or route of administration. There is no restriction for
presence or type of sedation protocol. Studies evaluating
the use of alpha-2 agonists solely for procedural sedation
will be excluded.
Comparators
The comparator of interest is any standard sedative regi-
men such as propofol, benzodiazepines, or opioids. This
includes between group comparisons and within group
comparisons (such as before-after designs). We antici-
pate a paucity of literature examining the safety and effi-
cacy of alpha-2 agonists for non-procedural sedation in
neurocritical care patients. As such, we will be as inclu-
sive as possible and include studies without a compara-
tor. No studies will be excluded for lack of or type of
comparator.
Outcomes
The primary goal of this review is to evaluate the safety
and efficacy of these agents with regard to neurophysio-
logic parameters. Complex patient-centered outcomes are
not expected to be available given the paucity of literature
and may be a reasonable focus of future study once safety
and efficacy is established. Therefore, the primary
outcomes of interest are mean arterial pressure (MAP),
intracranial pressure (ICP), and cerebral perfusion pres-
sure (CPP). These outcomes will be described as means,
within group mean differences, and across group mean
differences (before and after administration).
These primary outcomes were chosen as they repre-
sent the principal physiologic parameters optimized in
the management of the neurocritical care population.
Changes in these parameters, related or not to sedative
choice, can have a large impact on patient safety and
outcome. Given that we anticipate a great deal of hetero-
geneity in hemodynamic parameters reported by studies,
we will collect data on all parameters reported by
authors to ensure this review is as inclusive as possible.
No studies will be excluded based on the lack of
reported outcomes.
Secondary outcomes include adverse events as de-
fined by the study authors (including bradycardia,
hypotension, or any other adverse event), duration
of mechanical ventilation, incidence of delirium (as
assessed by the Confusion Assessment Method—ICU),
quality of sedation (Richmond Agitation–Sedation
scale or COMFORT score), ICU length of stay, and
30-day mortality.
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Study design
We will include all completed clinical studies reporting
the use of an alpha-2 agonist as a sedative in neurocriti-
cal care patients in our quantitative review, including
randomized controlled trials, quasi-randomized trials,
and retrospective and prospective cohort studies. There
will be no date or language restrictions. In-progress
studies identified from the clinicaltrials.gov registry and
CENTRAL Cochrane will be included in a qualitative
analysis. Letters to the editor, case reports, editorial
reviews, and guidelines will be excluded.
Data sources
A comprehensive literature search will be conducted in
MEDLINE and Embase using a pre-defined search strat-
egy as detailed below. There will be no restrictions on
language or time period. We will additionally hand-
search the reference lists of all primary studies and pre-
viously published systematic reviews for relevant studies.
The conference abstracts of the European Society of
Intensive Care Medicine Congress, Neurocritical Care
Society Annual Meeting, Pulmonary and Critical Care
Medicine, and Critical Care Canada Forum for the last
3 years will be searched, and the first authors of relevant
abstracts will be contacted for further information. To lo-
cate unpublished or ongoing trials, the clinicaltrials.gov
registry and CENTRAL Cochrane Library will be searched
as well.
Search strategy
A search strategy was developed under the guidance of a
health information specialist with expertise in clinical re-
search and was subsequently peer reviewed by a clinical
expert. Keywords were derived based on the population
of interest, neurocritical care patients, and the inter-
vention, alpha-2 agonists. The final search strategy is
comprised of both relevant Medical Subject Headings
(MeSH) and synonyms identified from the keywords.
The search strategies for MEDLINE and Embase are
available in Appendices 1 and 2, respectively. MEDLINE
and Embase will be searched through the Ovid interface.
Study selection process
Literature search results will be de-duplicated in End-
note software (version X7, Thomson Reuters) [21] and
then uploaded to Covidence, a web-based systematic re-
view tool that facilitates screening (online version, Alfred
Health) [22]. The assessors will not be blinded to author,
institution, or journal of publication. Titles and abstracts
will be independently screened for inclusion by two
reviewers (AT, HB), and disagreements will be resolved
by a clinical expert (SE) if needed. If insufficient infor-
mation is available from an abstract to determine eligi-
bility, the study will be included for a full-text review.
Full text reports will be independently assessed for eligi-
bility using an approach to that described for review of
abstracts. Reasons for excluding full-text articles will be
documented. The entirety of the study selection process
will be documented and presented using a flow diagram
within the final review as recommended by the PRISMA
statement [23].
Data collection and analysis
Data extraction and management
Data extraction will be performed independently and in
duplicate using a data collection form implemented in
Microsoft Excel 2013 that will be piloted a priori. Ab-
stracted data will include the following: publication char-
acteristics (study title, first author, year of publication,
country of study origin), key patient characteristics (age,
sex, primary ICU diagnoses, and primary neurological
diagnoses, injury severity/characteristics), intervention
and comparator characteristics (agent, dose, route,
sedation protocol, and adjunctive sedatives), outcome
data (including means/standard deviation or median/
interquartile and numbers of events and sample size for
binary endpoints), and study methods for the risk of bias
assessment described below. Disagreements in data
extraction will be resolved by consensus or by a third
reviewer with methodologic and clinical expertise as
required.
Assessing the risk of bias
The risk of bias in each included study will be assessed
independently by two reviewers. Disagreements will be
resolved by consensus or by a third reviewer with clin-
ical expertise if required. These assessments will be
completed for each individual outcome of interest. Risk
of bias for randomized controlled trials will be assessed
using the Cochrane Risk of Bias tool [24], which rates
bias as low risk, high risk, or unclear risk. This assess-
ment is based upon criteria which include sequence gen-
eration, allocation concealment, blinding, selective
outcome reporting, and presence of other biases. The
risk of bias for observational studies will be assessed
using the Newcastle-Ottawa Quality Assessment scale
[25]. This assessment, scored out of 9, is based on cri-
teria such as cohort and control selection, comparability
of the two groups as well as outcome assessment and
follow-up. All studies will be included in this review re-
gardless of their risk of bias.
Dealing with missing data
We will attempt to contact the corresponding authors of
studies with missing data up to two times via email. If
missing data is not located, available data will be
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analyzed and the potential impact of the missing data
will be discussed as a limitation.
Data synthesis
Where pooling of outcome data is appropriate, we will
use Comprehensive Meta-Analysis software (Version 3,
Biostat Inc) [26] to perform meta-analyses using a
random effects model. Effect sizes for each outcome will
be determined using the inverse-variance method. The
results will be presented as either mean differences with
95 % CI for continuous outcomes or event rates with
95 % CI for discrete counting events.
We anticipate considerable clinical heterogeneity in
the literature with regard to study design, clinical diag-
nosis, and definition of the outcome measures. In order
to address this concern, we will plan for the following
subgroup analyses:
1. Specific alpha-2 agonist (dexmedetomidine, cloni-
dine, other)
(a)Evaluated for all primary and secondary outcomes
2. Clinical diagnosis (TBI, stroke, hemorrhage, other)
(a)Evaluated for all primary and secondary outcomes
3. Dosing regimen (rapid dosing—IV bolus then
infusion, slow dosing—oral route or IV infusion
without bolus)
(a)Evaluated for adverse events
4. Adjunctive agents (other co-sedatives or analgesics,
none)
(a)Evaluated for adverse events, risk of delirium, and
quality of sedation
Statistical heterogeneity of study findings will be
assessed using the Cochrane Q and the I2 statistic in
order to determine appropriateness of data synthesis.
The I2 statistic values of 25, 50, and 75 % correspond to
low, moderate, and high heterogeneity, respectively. If
there is demonstration of significant heterogeneity as de-
fined by a p < 0.10 and an I2 statistic >75 %, then pooling
of data will not be performed. In such cases, the results
will be described qualitatively.
Sensitivity analysis
A sensitivity analysis may be used to restrict analysis to
randomized and prospective cohort study designs to as-
sess the influence of data from other study designs
which may be prone to increased bias. Post hoc sensitiv-
ity analyses will be performed where appropriate, includ-
ing those informed by risk of bias assessments.
Assessing the quality of evidence
The Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) approach will be used
to assess the quality of evidence for each outcome where
appropriate, but the anticipated heterogeneity of study
design may limit our ability to do so [27–32]. This
approach describes the level of confidence for which an
estimate of effect is close to the value of interest. The
overall quality of evidence is summarized as high, mod-
erate, low, or very low. The GRADE assessment is based
on the following criteria: risk of bias and study limita-
tions, directness, consistency of results, precision, publi-
cation bias, magnitude of effect, dose-response gradient,
and residual confounding. A final quality of evidence
grade and strength of recommendation (strong or weak)
will be provided for or against the intervention under
view.
Preparation of the completed review
The PRISMA statement and the meta-analysis of obser-
vational studies in epidemiology (MOOSE) checklist will
be used when drafting a summary report of the com-
pleted review [23, 33].
Discussion
While alpha-2 agonists such as dexmedetomidine and
clonidine have been shown to be an effective class of
sedative in the general critical care population, there is a
paucity of literature detailing their utility and safety in
neurocritical care. This systematic review will summarize
the evidence on the efficacy and safety for the use of
alpha-2 agonists as sedative agents in the neurocritical
care population.
Additional file
Additional file 1: PRISMA-P 2015 checklist.
Appendix 1
Search strategy for MEDLINE database
1 Adrenergic alpha-Agonists/
2 exp Adrenergic alpha-2 Receptor Agonists/




7 exp Intracranial Hemorrhages/















22 (cerebr* adj2 h?emorrhage*).tw.
23 intracerebr* h?emorrhage*.tw.










34 1 or 2 or 3 or 4 or 5 or 6
35 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or
16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25
or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33
36 34 and 35
Appendix 2
Search strategy for Embase database
1 alpha adrenergic receptor stimulating agent/
2 alpha 2 adrenergic receptor stimulating agent/
3 clonidine/
4 dexmedetomidine/




9 acquired brain injury/
10 diffuse axonal injury/
11 traumatic brain injury/
12 brain injury/
13 head injury/
14 exp cerebrovascular accident/













28 (cerebr* adj2 h?emorrhage*).tw.
29 intracerebr* h?emorrhage*.tw.





35 brain vascular accident*.tw.





41 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or
18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 37 or
38 or 39 or 40
42 36 and 41
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